Drug intelligence / Profile preview

PF-07260437

Development stage: Discontinued
Lead developer: Pfizer
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PF-07260437 is a bispecific monoclonal antibody developed by Pfizer that targets both B7-H4, a protein expressed on the surface of certain tumor cells, and CD3, a component of T cells. By binding to these two targets, PF-07260437 is designed to redirect T cells to attack and kill tumor cells expressing B7-H4. The drug acts through mechanisms including antibody-dependent cell cytotoxicity and stimulation of T lymphocytes. It was investigated for the treatment of advanced or metastatic solid tumors but development was discontinued after phase 1 trials[1][2][3][4].

Targets

CD3 (T-cell surface glycoprotein CD3)VTCN1 (V-set domain containing T cell activation inhibitor 1)

Beyond the preview

Go deeper on PF-07260437.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07260437.

Explore the full profile